The Michael J. Fox Foundation for Parkinson's Research (MJFF) is the world's largest non-profit funder of Parkinson's disease research, dedicated to finding a cure for PD and developing improved therapies for patients living with the disease. Founded in 2000 by actor Michael J. Fox following his diagnosis with Parkinson's disease, the Foundation has invested over $1 billion in research to date["@michael"].
The MJFF's mission is to find a cure for Parkinson's disease through aggressively funded research and to ensure the development of improved therapies for patients living with PD today[@michael].
The Foundation was established in 2000 after Michael J. Fox publicly disclosed his Parkinson's diagnosis, signaling his commitment to accelerating research toward a cure. A major milestone occurred in 2010 with the launch of the Parkinson's Progression Markers Initiative (PPMI), followed by expansion of the LEDA study for exercise research in PD in 2014. The Foundation reached a historic $1 billion in total research funding by 2020 and launched the Parkinson's Disease Data Portal in 2019. By 2022, PPMI entered a new phase focused on prodromal and early PD, and the Foundation has continued expanding its drug repurposing and clinical trial programs through 2024[@fox2024].
PPMI is one of the most significant Parkinson's research databases in the world, established to identify biomarkers of PD progression through a landmark observational clinical study using a multi-modal approach that includes clinical assessments for motor and non-motor symptom tracking, collection of biological samples such as blood, CSF, and DNA, advanced imaging techniques including DaTscan, MRI, and PET, and digital tracking via smartphone-based symptom monitoring[@auto_41869750]. The study has enrolled over 1,500 participants spanning newly diagnosed PD patients, at-risk individuals carrying LRRK2 or GBA mutations, and healthy controls. PPMI data is openly shared with researchers worldwide through an accessible data portal, accelerating drug development and repurposing efforts[@parkinsons]. Key discoveries from PPMI include the detection of abnormal alpha-synuclein seeding in CSF, improved understanding of genetic risk profiling for LRRK2 and GBA carrier phenotypes, identification of prodromal markers as early warning signs, and validation of progression biomarkers. All anonymized datasets are freely available to researchers globally, with biological samples accessible through the biobank and collaborative projects encouraged through the PPMI network.
The MJFF funds numerous clinical trials focusing on disease modification through therapies that slow or halt PD progression, alpha-synuclein targeting using antibodies, vaccines, and small molecules, LRRK2 inhibitors for patients with LRRK2 mutations, GBA1 modulators for those with GBA1 mutations, and symptomatic treatments including improved dopaminergic and non-dopaminergic therapies[@michael].
The MJFF actively supports drug repurposing through target validation programs that de-risk novel targets for pharmaceutical company investment, clinical trial networks providing infrastructure to rapidly test repurposed compounds, biomarker development enabling patient selection for targeted trials, and international coordination that aligns global efforts for maximum impact.
| Area | Focus |
|------|-------|
| Alpha-Synuclein | Antibodies, vaccines, aggregation inhibitors |
| LRRK2 | Kinase inhibitors for LRRK2-associated PD |
| GBA1 | Gene therapy and small molecule modulators |
| Neuroinflammation | Microglial and immune targets |
| Mitochondrial Function | Energy metabolism and mitophagy |
| Neuroprotection | Synaptic and neuronal survival |
| Biomarkers | Early diagnosis and progression markers |
The MJFF offers multiple grant programs to support the therapeutic pipeline from discovery through clinical trials, including the Therapeutic Pipeline Program for drug development, Clinical Trial Planning grants to help prepare for upcoming clinical studies, Postdoctoral Fellowships to train the next generation of PD researchers, and Team Awards to support collaborative, multi-institutional projects.
The Foundation partners with pharmaceutical and biotechnology companies to de-risk drug development through co-funding clinical trials, providing patient registry access, sharing biomarker data, and supporting regulatory interactions.
Michael J. Fox serves as Founder and Chairman of the Foundation. Debi Brooks led as Chief Executive Officer from 2002 to 2022, followed by Todd Sherer, PhD who has served as CEO since 2022. Katherine S. Hunt, MS holds the position of Chief Scientific Officer.
The MJFF operates as a 501(c)(3) non-profit organization that has invested over $1 billion in total research since its inception, with an annual research budget of approximately $100-150 million. Funding is derived from individual donors, corporate partners, and foundation grants.
The MJFF has been instrumental in advancing drug repurposing for PD by identifying repurposing candidates through PPMI data and biomarker studies, funding clinical trials of drugs originally approved for other conditions, creating infrastructure for rapid testing of repurposed compounds, and coordinating international efforts to avoid duplication and maximize resources. Notable repurposing efforts supported by MJFF include GLP-1 receptor agonists originally developed for diabetes, inosine originally for gout, various kinase inhibitors, and anti-inflammatory agents.
PPMI is a landmark observational clinical study designed to identify biomarkers of PD progression using a multi-modal approach that combines clinical assessments for motor and non-motor symptom tracking, collection of biological samples including blood, CSF, and DNA, advanced imaging techniques such as DaTscan, MRI, and PET, and digital tracking via smartphone-based symptom monitoring.
PPMI has yielded numerous important findings including the detection of abnormal alpha-synuclein seeding in CSF, improved understanding of genetic risk profiling through LRRK2 and GBA carrier phenotypes, identification of prodromal markers as early warning signs, and validation of progression markers for clinical use.
All PPMI data is freely available to researchers worldwide through an open access data portal containing anonymized datasets, with biological samples available for request through the biobank, custom analysis tools for data exploration, and collaborative projects encouraged through the PPMI network.
MJFF has built a global clinical trial infrastructure comprising a network of academic medical centers as trial sites, access to well-characterized patient populations through patient registries, standardized assessment protocols for outcome measures, and regulatory expertise providing guidance for trial design and execution.
The Foundation supports numerous ongoing trials spanning Phase 1 first-in-human safety studies, Phase 2 dose-finding and efficacy signal studies, and Phase 3 large-scale confirmatory trials.
Key trial outcomes include Exenatide, a GLP-1 agonist showing disease-modifying potential, Inosine for urate elevation and neuroprotection, Nilotinib, a tyrosine kinase inhibitor for PD, and various alpha-synuclein targeting therapies currently in development.
MJFF partners with pharmaceutical companies through co-funding arrangements for shared investment in clinical trials, data sharing providing access to PPMI and other datasets, regulatory support for collaborative FDA interactions, and joint target validation to de-risk novel targets.
The Foundation supports academic research through research grants funding academic investigators, training programs including fellowships for young investigators, and consortium work for multi-site collaborative projects.
Global collaboration is central to MJFF strategy, engaging with the International Parkinson's Genetics Project (IPGD), Global Parkinson's Genetics Program (GP2), Parkinson's Foundation, and European PD Research Networks.
MJFF manages Fox Insight, a large patient-reported outcome platform that also provides clinical trial matching to connect patients with appropriate trials and supports natural history studies to understand disease progression.
The Foundation educates and advocates through provider education programs training healthcare professionals, public awareness initiatives reducing stigma and increasing understanding, and policy advocacy supporting research funding and access to care.
Research priorities are patient-driven through patient advisory boards providing input on research direction, quality of life studies focused on patient-relevant outcomes, and caregiver support research addressing caregiver burden and needs.
Early achievements included establishment of research programs, initial clinical trial funding, and creation of patient registry infrastructure that would support future expansion.
Major developments during this period encompassed the launch and expansion of PPMI, reaching $1 billion in total research funding, and multiple clinical trial successes that advanced therapeutic candidates.
Current priorities focus on genetic subtyping of PD, biomarker-driven clinical trials, and personalized therapeutic approaches tailored to individual patient characteristics.
The Foundation continues to expand into new areas including gene therapy for AAV-based delivery and gene editing approaches, cell replacement through stem cell and cell-based therapies, digital health leveraging wearables and remote monitoring, and AI/ML computational approaches to biomarker discovery.
Current strategic priorities include alpha-synuclein targeting through antibodies, vaccines, and aggregation inhibitors, development of targeted therapies for genetic forms of PD including LRRK2, GBA, and other mutations, biomarker development creating tools for patient selection and response monitoring, and disease modification through therapies that slow or halt progression.
MJFF continues to have global impact by training the next generation of PD researchers, accelerating drug development timelines, improving patient outcomes through better therapies, and building international collaboration networks.
MJFF recognizes outstanding contributions through the Morris K. Yahr Prize for excellence in Parkinson's research, Team Grants supporting collaborative research initiatives, and Young Investigator Awards for early-career researchers.
Training the next generation is supported through Postdoctoral Fellowships for recent PhDs, Clinical Fellowships training clinician-scientists, and Graduate Student Support providing research experience for students.
The Foundation is governed by medical and scientific advisors, patient representatives, business and financial experts, and legal and compliance professionals.
Leading researchers guide strategy including academic leaders in neurodegeneration, clinical experts in movement disorders, and industry representatives from pharmaceutical and biotechnology companies.
The Foundation maintains audited financial statements ensuring transparent accounting, efficient operations with low overhead and high impact, and strategic allocation focused on highest-impact research.